ImmunoCellular suspends Phase III GBM trial of ICT-107 for lack of cash

ImmunoCellular Therapeutics Ltd. (NYSE-M:IMUC) suspended enrollment for financial reasons in its Phase III trial evaluating ICT-107 to treat newly diagnosed glioblastoma multiforme (GBM). The company

Read the full 259 word article

How to gain access

Continue reading with a
two-week free trial.